QBW 276

Drug Profile

QBW 276

Alternative Names: QBW276

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 27 Sep 2017 Phase-I/II clinical trials in Cystic fibrosis in Germany, United Kingdom (Inhalation) (NCT02566044) (EudraCT2014-004915-35)
  • 18 Sep 2015 Novartis plans a phase I/II trial for Cystic fibrosis in USA, United Kingdom and Germany (NCT02566044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top